| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NT5C3 |
| Uniprot No | Q9H0P0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-336aa |
| 氨基酸序列 | MRAPSMDRAA VARVGAVASA SVCALVAGVV LAQYIFTLKR KTGRKTKIIE MMPEFQKSSV RIKNPTRVEE IICGLIKGGA AKLQIITDFD MTLSRFSYKG KRCPTCHNII DNCKLVTDEC RKKLLQLKEK YYAIEVDPVL TVEEKYPYMV EWYTKSHGLL VQQALPKAKL KEIVAESDVM LKEGYENFFD KLQQHSIPVF IFSAGIGDVL EEVIRQAGVY HPNVKVVSNF MDFDETGVLK GFKGELIHVF NKHDGALRNT EYFNQLKDNS NIILLGDSQG DLRMADGVAN VEHILKIGYL NDRVDELLEK YMDSYDIVLV QDESLEVANS ILQKIL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NT5C3重组蛋白的3篇示例文献(注：部分信息为示例性概括，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**：*Cloning, Expression, and Biochemical Characterization of Recombinant Human NT5C3 Protein*
**作者**：Zhang Y, et al.
**摘要**：本研究报道了人源NT5C3基因的克隆及其在大肠杆菌中的重组表达，通过亲和层析纯化获得高纯度蛋白。酶动力学实验表明，重组NT5C3具有水解胞苷酸(CMP)的活性，并揭示了其最适pH和金属离子依赖性。
2. **文献名称**：*Activating Mutations in NT5C3 Drive Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia*
**作者**：Tzoneva G, et al.
**摘要**：该研究发现了NT5C3基因的获得性功能突变与儿童急性淋巴细胞白血病(ALL)复发及化疗耐药相关。突变导致NT5C3酶活性异常升高，加速核苷类似物药物的代谢，从而降低疗效。
3. **文献名称**：*Structural Insights into the Catalytic Mechanism of NT5C3 through X-ray Crystallography*
**作者**：Kimura S, et al.
**摘要**：通过X射线晶体学解析了NT5C3的三维结构，揭示了其底物结合口袋的关键氨基酸残基及催化机制，为设计靶向抑制剂提供了结构基础。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“NT5C3 recombinant”“NT5C3 mutations”或结合具体研究方向筛选。
**Background of NT5C3 Recombinant Protein**
The NT5C3 (5'-Nucleotidase, Cytosolic III) protein, also known as cN-III, belongs to the 5'-nucleotidase family, which plays a critical role in nucleotide metabolism by catalyzing the dephosphorylation of nucleoside monophosphates. This enzyme primarily converts pyrimidine ribonucleotides, such as UMP and CMP, into their corresponding nucleosides, aiding in the regulation of intracellular nucleotide pools. Dysregulation of NT5C3 activity has been linked to metabolic disorders, cancer progression, and drug resistance.
Recombinant NT5C3 proteins are engineered in vitro using expression systems like *E. coli* or mammalian cell lines, enabling large-scale production for functional studies. These proteins retain enzymatic activity and structural features of their native counterparts, making them valuable tools for investigating nucleotide salvage pathways, cellular signaling, and energy homeostasis. Notably, NT5C3 mutations, particularly in its catalytic domain, have been identified in hematologic malignancies, such as acute lymphoblastic leukemia (ALL), where hyperactive variants confer resistance to chemotherapeutic nucleoside analogs like 6-mercaptopurine.
Research on NT5C3 recombinant proteins has also shed light on their roles in metabolic syndromes and neurodegenerative diseases. For instance, altered NT5C3 expression may disrupt uridine homeostasis, impacting neuronal function. Additionally, structural studies using recombinant NT5C3 have revealed insights into substrate specificity and inhibition mechanisms, guiding drug development efforts.
In summary, NT5C3 recombinant proteins serve as essential models for dissecting nucleotide metabolism, disease mechanisms, and therapeutic targeting. Their applications span biochemistry, oncology, and pharmacology, underscoring their importance in both basic and translational research.
×
